Notícias e Atividades da C4 Therapeutics

C4 Therapeutics é uma empresa listada sob o símbolo CCCC (US).

Veja o organograma con seus 27 executivos principais

Biografias mais buscadas da C4 Therapeutics

• Andrew Hirsch, Chief Executive Officer and Director
• Utpal Koppikar, Director
• Donna Grogan, Director

Criar um alerta
para seguir os movimentos de executivos da C4 Therapeutics.

C4 Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de C4 Therapeutics

• C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights – C4 Therapeutics
• C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors – C4 Therapeutics
• C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors – C4 Therapeutics
• C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights – C4 Therapeutics
• C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader – C4 Therapeutics
• C4 Therapeutics Appoints Utpal Koppikar to Board of Directors – C4 Therapeutics
• C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma – C4 Therapeutics
• C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022  – C4 Therapeutics
• C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights – C4 Therapeutics
• C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio – C4 Therapeutics
• View more press releases Close

Redes sociais sobre C4 Therapeutics

• C4 Therapeutics na Wikipedia, Google News e Yahoo Finance
• C4 Therapeutics na LinkedIn, X (Twitter) e YouTube